IASO Biotherapeutics USA
17 articles about IASO Biotherapeutics USA
-
IASO Bio Announces CT103A Granted Regenerative Medicine Advanced Therapy (RMAT) and Fast Track (FT) Designations by the FDA
2/13/2023
IASO Biotherapeutics announced that the U.S. Food and Drug Administration has granted both Regenerative Medicine Advanced Therapy designation and Fast Track designation to its investigational new drug BCMA CAR-T CT103A for relapsed/refractory multiple myeloma.
-
IASO Bio Raises Nearly $75 Million in Series C1 Funding
1/17/2023
IASO Biotherapeutics (IASO Bio), a clinical-stage biopharmaceutical company engaged in discovering, developing, and manufacturing innovative cell therapies and antibody products, today announced the completion of nearly US $75 million ($500 million RMB) in Series C1 funding.
-
U.S. FDA Approves Clinical Trial Application for IASO Bio's BCMA CAR-T CT103A for Relapsed/Refractory Multiple Myeloma
12/22/2022
IASO Biotherapeutics announced that the Investigational New Drug application for its in-house developed BCMA CAR-T CT103A has been approved by the U.S. Food and Drug Administration for use in U.S. clinical trials for relapsed/refractory multiple myeloma.
-
Umoja Biopharma and IASO Biotherapeutics Announce Research Collaboration to Bring Off-the-Shelf Therapies to Patients with Hematological Malignancies
11/21/2022
Umoja Biopharma, Inc. and IASO Biotherapeutics announced today that they have entered into a research agreement to evaluate Umoja's iCIL platform with IASO's best-in-class CARs,
-
IASO Biotherapeutics and Cabaletta Bio Announce Exclusive Worldwide License Agreement for Clinically Validated CD19 Binder
10/11/2022
IASO Biotherapeutics and Cabaletta Bio, Inc. today announced that the companies entered into an agreement pursuant to which Cabaletta obtained from IASO Bio an exclusive, worldwide license to develop, manufacture and commercialize a clinically validated fully-human CD19 binder for use in product that is designed to modify T cells in treatment of autoimmune diseases.
-
World's First CAR-T for NMOSD Treatment, IASO Biotherapeutics' Equecabtagene Autoleucel, Receives IND Approval by NMPA
8/19/2022
IASO Biotherapeutics announced that the Center for Drug Evaluation of China's National Medical Products Administration approved its investigational new drug application for the new extended indication of Neuromyelitis Optica Spectrum Disorder for a fully human BCMA chimeric antigen receptor autologous T cell Injection.
-
IASO Bio and Innovent Present Updated Data of BCMA CAR-T Cell Therapy (Equecabtagene Autoleucel) at EHA 2022
6/13/2022
IASO Biotherapeutics and Innovent Biologics, Inc. jointly announced that the updated data from phase 1/2 study of Equecabtagene Autoleucel, a fully-human anti-B cell maturation antigen chimeric antigen receptor T-cell therapy for the treatment of relapsed and/or refractory multiple myeloma, was presented in the form of an oral presentation at the 27th European Hematology Association Annual Meeting in Vienna on June 9-12, 2022.
-
Innovent and IASO Bio Jointly Announce the NMPA Acceptance of the New Drug Application for Equecabtagene Autoleucel for the Treatment of Relapsed and/or Refractory Multiple Myeloma
6/6/2022
Innovent Biologics, Inc. and IASO Biotherapeutics jointly announced that the China National Medical Products Administration has formally accepted the New Drug Application for Equecabtagene Autoleucel, a fully human anti-B cell maturation antigen chimeric antigen receptor T-cell therapy for the treatment of relapsed and/or refractory multiple myeloma.
-
IASO Bio and Innovent Jointly Announce the NMPA Acceptance of the New Drug Application for Equecabtagene Autoleucel for the Treatment of Relapsed and/or Refractory Multiple Myeloma
6/2/2022
IASO Biotherapeutics ("IASO Bio"), and Innovent Biologics, Inc. ("Innovent," HKEX: 01801), today jointly announced that the China National Medical Products Administration (NMPA) has formally accepted the New Drug Application (NDA) for Equecabtagene Autoleucel (IASO Bio R&D code: CT103A, Innovent R&D code: IBI326).
-
IASO Biotherapeutics' Equecabtagene Autoleucel, the World's First CAR-T for Treatment of NMOSD, Receives IND Application Acceptance by NMPA
5/28/2022
IASO Biotherapeutics announced that China's National Medical Products Administration has accepted its investigational new drug application for the new extended indication of Neuromyelitis Optica Spectrum Disorder for a fully human BCMA chimeric antigen receptor autologous T cell Injection.
-
U.S. FDA Grants Orphan Drug Designation to BCMA CAR-T Cell Therapy Co-Developed by IASO Bio and Innovent
2/14/2022
IASO Biotherapeutics and Innovent Biologics, Inc. jointly announced that the Office of Orphan Products Development of the U.S. Food and Drug Administration has granted Orphan Drug Designation to their fully human anti-B-cell maturation antigen chimeric antigen receptor T-cell therapy for the treatment of relapsed and/or refractory multiple myeloma.
-
U.S. FDA Grants Orphan Drug Designation to BCMA CAR-T Cell Therapy Co-Developed by Innovent and IASO Bio
2/14/2022
Innovent Biologics, Inc. together with IASO Biotherapeutics jointly announced that the U.S. Food and Drug Administration's Office of Orphan Products Development has formally granted Orphan Drug Designation to their co-developed fully-human B-cell maturation antigen -targeted chimeric antigen receptor T-cell therapy for the treatment of patients with relapsed/refractory multiple myeloma.
-
Seattle-based Sana Biotechnology went all-in on improving CAR T therapies against B cell cancers in two separate deals announced today.
-
IASO Biotherapeutics and Innovent Biologics Announced Updated Clinical Data of BCMA CAR-T Therapy in Oral Presentation at 2021 ASH Annual Meeting
12/13/2021
IASO Biotherapeutics and Innovent Biologics, Inc. jointly announced the latest data from the phase 1/2 clinical study of a fully human B-cell maturation antigen chimeric antigen receptor T-cell therapy in an oral presentation at the 63rd American Society of Hematology Annual Meeting.
-
Innovent and IASO Announced Updated Clinical Data of BCMA CAR-T Therapy in Oral Presentation at 2021 ASH Annual Meeting
12/13/2021
Innovent Biologics, Inc and IASO Biotherapeutics jointly announced the latest data from the phase 1/2 clinical study of a fully human B-cell maturation antigen chimeric antigen receptor T-cell therapy in an oral presentation at the 63rd American Society of Hematology Annual Meeting.
-
IASO Biotheraputics' CT120 Granted Orphan Drug Designation by the U.S. FDA
11/26/2021
IASO Biotherapeutics announced on Oct 26, 2021 that the Office of Orphan Products Development of the U.S. Food and Drug Administration has granted the Orphan Drug Designation to the company's in-house developed fully human CD19/CD22 dual-targeted chimeric antigen receptor -T cell therapy for the treatment of acute lymphoblastic leukemia.
-
IASO Bio Appoints Industry Veteran Dr. Alan Fu Chief Financial Officer
10/19/2021
IASO Biotherapeutics has appointed Dr. Alan Fu as Chief Financial Officer (CFO), reporting to Maxwell Wang, CEO, IASO Bio.